How to Review

Premium

 

When NIH comes calling on assistant professors to sit as ad hoc members of a study section, many aren't quite sure what to expect. Never fear: two seasoned study section members offer their advice and thoughts on why researchers should sit on sections.

The University of Pittsburgh's Richard Chaillet had been a faculty member for about three years when he first sat in on an NIH study section. Initially, NIH asks researchers to be ad hoc reviewers, who look at a small number of grants and attend a study section.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.